Vertex Pharmaceuticals Incorporated (VRTX)
210.11 -2.87 (-1.35%)
Pre-market: 4:53AM EST
| Previous close | 217.04 |
| Open | 215.80 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's range | 210.50 - 217.40 |
| 52-week range | 197.47 - 306.08 |
| Volume | 1,830,557 |
| Avg. volume | 1,927,508 |
| Market cap | 55.366B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | 20.70 |
| EPS (TTM) | 10.29 |
| Earnings date | 27 Apr 2021 - 03 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 284.73 |
- Business Wire
Vertex to Present at the Cowen Health Care Conference on March 2
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET.
- Motley Fool
Forget Bitcoin: 4 Stocks to Buy Hand Over Fist Instead
Since the March 23 bear market low, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite are up a cool 70%, 76%, and 104%, respectively. Many of the same theses that bulls have extolled for years continue to drive Bitcoin's ascent. For example, fans still view its 21 million token limit as a hedge against the long-term devaluation of the U.S. dollar as the money supply increases.
- Motley Fool
What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash?
Vertex Pharmaceuticals (NASDAQ: VRTX) has $6.6 billion in the bank and continues to generate more cash flow each quarter. While Vertex has some early stage drugs that could generate revenue in a few years, the company is also looking to buy growth through the acquisition of a late-stage pipeline candidate or two (or three). In this video from Motley Fool Live recorded on Feb. 8, Fool.com contributors Brian Orelli and Keith Speights discuss the biotech's pipeline and where it might expand beyond cystic fibrosis.
